Non-alcoholic steatohepatitis treatment market to reach $18.97 billion by 2030 at 39.7% cagr, driven by increased prevalence of insulin resistance.
Read MoreNon-alcoholic steatohepatitis (nash) market to reach $24.32 billion by 2030 at 31.9% cagr, driven by rising cases of obesity.
Read MoreNon hodgkin lymphoma (nhl) market to reach $16.44 billion by 2030 at 8.8% cagr, driven by high prevalence of non-hodgkin lymphoma.
Read MoreNocturnal enuresis medication market to reach $2.26 billion by 2030 at 6.7% cagr, driven by increasing demand for personalized care and rising healthcare expenditure.
Read MoreNivolumab market to reach $3.63 billion by 2030 at 13.8% cagr, driven by increased incidence of non-small cell lung cancer and rising adoption of personalized medicine.
Read MoreNitrogen mustards market to reach $4.65 billion by 2030 at 5.8% cagr, driven by increasing prevalence of cancer and adoption of personalized medicine.
Read MoreNimesulide dispersible tablet market to reach $1.16 billion by 2030 at 7.0% cagr, driven by increasing prevalence of musculoskeletal disorders and chronic pain.
Read MoreNicotine replacement therapy market to reach $4.54 billion by 2030 at 5.6% cagr, driven by rising incidence of smoking-related diseases.
Read MoreNicotine addiction treatment market to reach $6.21 billion by 2030 at 10.1% cagr, driven by rising prevalence of tobacco addiction among teenagers.
Read MoreNext generation tissue biomarkers market to reach $5.51 billion by 2030 at 12.6% cagr, driven by rising demand for personalized medicine.
Read More
